Lytica Therapeutics is accepted into the Blue Knight program, a joint initiative by Johnson & Johnson Innovation and BARDA
Rida Mourtada, Lytica's Chief Scientific Officer, discusses the importance of push mechanisms in revitalizing the antibiotic pipeline at the Milken Global Conference
Loren Walensky, Lytica Scientific Cofounder, recognized by Nature Biotechnology as One of the World's Top 20 Translational Researchers of 2019
Lytica Therapeutics Receives CARB-X Award For Up To $16.9 Million To Develop Antimicrobial Peptides To Treat Drug-Resistant Infections
Stapled Antimicrobial Peptide Design, as published in the October Issue of Nature Biotechnology
Copyright © 2019-2022 Lytica Therapeutics, Inc - All Rights Reserved.
This website uses cookies. By continuing to use this site, you accept our use of cookies.